e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 2, 2010
EZCORP, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
(State or other jurisdiction of incorporation)
|
|
0-19424
(Commission File Number)
|
|
74-2540145
(IRS Employer
Identification No.) |
1901 Capital Parkway, Austin, Texas 78746
(Address of principal executive offices) (zip code)
Registrants telephone number, including area code: (512) 314-3400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
|
|
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers
(c) |
|
On November 2, 2010, EZCORP, Inc. announced the appointment of Stephen A. Stamp as Senior
Vice President and Chief Financial Officer (principal financial officer), effective
immediately. A copy of the companys press release announcing this appointment is attached as
Exhibit 99.1 and incorporated herein by reference. |
|
|
Mr. Stamp, age 48, has over 27 years of finance and business experience, having previously
served as Chief Financial Officer and Chief Operating Officer of Xanodyne Pharmaceuticals;
Group Finance Director at Regus Group PLC; and Group Finance Director at Shire
Pharmaceuticals Group PLC. Mr. Stamps career also includes various roles at Lazard Brothers
& Company Ltd. and KPMG. Most recently, Mr. Stamp served as Chief Financial Officer at KV
Pharmaceutical Company. |
|
|
Under the terms of his employment, Mr. Stamp will receive an annual salary of $350,000, a
target bonus of 60% of base salary, and 20,000 restricted shares of EZCORP Class A Non-Voting
Common Stock, which will vest pro rata on the first, second and third anniversaries of the
date of grant (assuming continued employment). Mr. Stamp will also be eligible for
relocation benefits and other benefits typically provided to the companys executive
officers. These benefits include a severance plan that provides for salary continuation for
a period one year if the company terminates Mr. Stamps employment without cause. |
|
|
|
Item 9.01 |
|
Financial Statements and Exhibits. |
|
|
|
|
|
|
99.1 |
|
|
Press Release, dated November 2, 2010 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
EZCORP, INC.
|
|
Date: November 2, 2010 |
By: |
/s/ Thomas H. Welch, Jr.
|
|
|
|
Thomas H. Welch, Jr. |
|
|
|
Senior Vice President,
General Counsel and Secretary |
|
|
2
EXHIBIT INDEX
|
|
|
|
|
Exhibit |
|
|
No. |
|
Description of Exhibit |
|
99.1 |
|
|
Press Release, dated November 2, 2010 |
3
exv99w1
Exhibit 99.1
EZCORP ANNOUNCES NEW CHIEF FINANCIAL OFFICER
AUSTIN, Texas (November 2, 2010) EZCORP, Inc. (Nasdaq: EZPW) announced today the
appointment of Stephen A. Stamp as Senior Vice President and Chief Financial Officer.
Mr. Stamp has over 27 years of finance and business experience. Most recently, Mr. Stamp served as
Chief Financial Officer at KV Pharmaceutical Company, a U.S. based manufacturer of generic and
branded drugs. He previously spent five years at Xanodyne Pharmaceuticals, a U.S. based specialty
pharmaceutical company, where he served as Chief Financial Officer and for one year as Chief
Operating Officer. Prior to his time at Xanodyne, Mr. Stamp spent over three years as Group
Finance Director at Regus Group PLC, a publicly traded, United Kingdom based office services
company with operations in over 50 countries; and six years as Group Finance Director at Shire
Pharmaceuticals Group PLC, a publicly traded international specialty pharmaceutical company
headquartered in the U.K. Mr. Stamps career also includes various roles at Lazard Brothers &
Company Ltd. and KPMG. Mr. Stamp graduated from the University of Manchester with a degree in
Business Finance. He is a Chartered Accountant in the U. K.
Paul Rothamel, EZCORPs President and Chief Executive Officer, stated: Stephen is a seasoned
executive who not only brings great finance and accounting experience, but is also a proven
business leader well versed in both U.S. and international issues. Stephen has led a variety of
finance organizations and has managed numerous complex financing transactions, acquisitions,
systems integrations, and cost-containment initiatives. I am excited to add such a successful
operational leader and proven strategic thinker to my executive leadership team. His contributions
will be invaluable as we continue the strategic growth of EZCORP.
About EZCORP
EZCORP is a leading pawn store operator and provider of specialty consumer financial services.
It provides collateralized non-recourse loans, commonly known as pawn loans, and a variety of
short-term consumer loans, including payday loans, installment loans and auto title loans, or
fee-based credit services to customers seeking loans. At its pawn stores, the company also sells
merchandise, primarily collateral forfeited from its pawn lending operations.
EZCORP operates more than 1,000 stores, including more than 500 pawn stores in the U.S. and Mexico
and more than 500 short-term consumer loan stores in the U.S. and Canada. The Company also has
significant investments in Albemarle & Bond Holdings PLC (ABM.L), one of the U.K.s largest
pawnbroking businesses with over 120 stores, and Cash Converters International Limited (CCV.L and
CCV.AUS), which franchises and operates a worldwide network of over 500 stores that provide
financial services and sell pre-owned merchandise.
For additional information, contact Investor Relations at (512) 314-2220.